Research programme: small molecule therapeutics - Epigenetix
Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Epigenetix
- Class Small molecules
- Mechanism of Action Amyloidogenic protein inhibitors; Protein-arginine N-methyltransferase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Anxiety disorders; Autistic disorder; Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Alzheimer's-disease in Canada
- 28 Jul 2018 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Jul 2018 No recent reports of development identified for research development in Anxiety-disorders in Canada